Irhythm Technologies ((IRTC)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
iRhythm Technologies is conducting the Pediatric Adhesion and New Dermal Approach Study (PANDA) to evaluate the feasibility of using the Zio® monitor in children. The study aims to determine if the device can be worn for up to 14 days while maintaining good skin adherence and clear signal quality. This research is significant as it could expand the use of the Zio® monitor to pediatric patients, potentially improving diagnostic capabilities for conditions like arrhythmia in children.
The intervention being tested is the Zio® monitor, a battery-powered adhesive patch worn on the upper left chest. It functions as a heart monitor, tracking heart rhythm and rate, similar to a band-aid in appearance.
The study employs a single-group interventional model with no masking, focusing on diagnostic purposes. Participants will wear the Zio® monitor to assess its performance over a 14-day period.
The study began on August 5, 2025, with the latest update submitted on September 8, 2025. These dates are crucial as they indicate the study’s current recruiting status and ongoing progress.
This update could positively influence iRhythm Technologies’ stock performance by showcasing innovation and expanding market reach. Investors may view this as a strategic move to capture a new demographic, potentially enhancing competitive positioning in the medical device industry.
The PANDA study is currently recruiting, with further details available on the ClinicalTrials portal.